1099-K reporting for peptide operators in 2026

Your accountant just forwarded you three 1099-K forms. One from the Authorize.net acquirer behind two of your peptide brands, one from the NMI account on the third, and one straggler from the Stripe account that closed in March but still reported the volume it processed before the freeze. The numbers do not match your bank deposits, they do not match your sales reports, and tax season is six weeks out. This is the annual reconciliation headache for every multi-brand peptide operator, and the $5,000 threshold means it is no longer just the big books that get the forms. Here is how to make the numbers reconcile and how to think about the gross figure that the IRS now sees.

What changed and why every peptide operator is affected

The IRS 1099-K reporting threshold is $5,000 for 2026. That is the dollar figure at which a payment settlement entity must file a 1099-K reporting your gross card volume to the IRS. There is no transaction-count requirement layered on top the way there used to be. Five thousand dollars in card sales through one processor and a form gets filed.

For peptide operators this means effectively everyone gets reported now. Even a single-brand operator doing modest volume clears $5,000 in a few weeks. The era where small peptide stores flew under a 200-transaction count is over. Plan as if every dollar you process is visible to the IRS, because it is.

Who actually files your 1099-K

The form comes from the payment settlement entity, which is the party that moves money to your bank account. That is your acquirer or your gateway/processor, not multiflow and not your shopping cart. This distinction matters for a multi-brand peptide operator because it determines how many forms land in your inbox.

• One MID per brand on separate acquirers means one 1099-K per brand.
• A parent account consolidating brands under one settlement entity means one 1099-K covering the consolidated volume.
• A closed processor still files a 1099-K for the volume it settled before closing, so a Stripe account that froze mid-year still reports.

multiflow is the orchestration layer on top of your acquirers. We do not settle funds, so we do not issue a 1099-K. The acquirer behind the parent account does. If you are unclear who your settlement entity is on each brand, that is the first thing to nail down before reconciliation.

Why the gross number never matches your deposits

The single most common panic is an operator seeing a 1099-K gross figure far larger than what hit their bank account. That is expected. The 1099-K reports gross processing volume before any deductions. Your deposits are net of a long list of subtractions.

So the bridge from the 1099-K gross to your deposits is: gross, minus refunds, minus chargebacks, minus fees, minus reserve currently held, plus reserve released from prior periods. Build that reconciliation per processor and the numbers tie out. Skip it and your accountant either overstates income or scrambles in April.

The trap is treating the 1099-K gross as your revenue. It is not. It is the total your card customers were charged, gross of everything that flowed back out. An operator who reports the 1099-K number as income pays tax on money that went to refunds, to lost chargebacks, to processing fees, and to a reserve still sitting at the acquirer. On a peptide book with heavy refunds and a 10-15% reserve, that overstatement can be enormous. The 1099-K is an informational document that tells the IRS what to look for, not a statement of what you earned. Your actual revenue comes off your own books, reconciled against the form, never the other way around.

Reserves are the peptide-specific wrinkle

Peptide operators carry heavy reserves, commonly 10-15% rolling over 180 days in year one. That money was processed, so it is in the 1099-K gross, but it is not in your bank account yet. It sits in a rolling reserve the acquirer holds against future chargebacks.

This creates a timing mismatch every peptide operator needs to track. Volume processed in Q4 with a 180-day reserve does not fully hit your account until the following year. Your books need to recognize the revenue and the reserve correctly so you are not paying tax on cash you have not received while also not forgetting income that will land later. Track every reserve hold and every release by date. The reserve calculation guide shows how to read the hold and release schedule from your statements.

Multi-brand reconciliation in practice

Running three or more peptide brands across multiple MIDs means multiple 1099-K forms that must roll up to one set of books. The work is matching each form to the right brand, reconciling each one through the gross-to-net bridge above, and confirming the sum ties to your accounting system.

This is exactly where the parent-account structure earns its cost. One settlement entity means one 1099-K and one reconciliation instead of one per brand. If you are still on separate MIDs per brand, the annual 1099-K scramble is one of the real costs that the true cost of multiple MIDs breakdown quantifies. The reconciliation labor is a line item people forget when they compare a 3.5% specialist rate to a 6% orchestrated rate.

Walk through a concrete year-end. Four brands, four MIDs, four 1099-K forms, each with its own gross, its own refund and chargeback totals, its own fee schedule, and its own reserve hold and release calendar. Your accountant has to reconcile each form independently, then roll the four up, then make sure no brand was double-counted because a customer who bought across two brands appears in two grosses. That is a full day of work in a good year and a multi-day mess in a bad one, every spring. Collapse those four onto one parent account and the same year-end is one form, one bridge, one reconciliation. The peptide operators overview frames where that consolidation makes sense by brand count, and the orchestration approach is compared directly against staying on a Stripe-style platform in multiflow vs Stripe for peptides. Neither is a tax decision, but the reporting drag is a real cost that belongs in the comparison.

Watch for state thresholds and corrected forms

The $5,000 figure is the federal threshold, but several states set their own lower reporting thresholds and require a 1099-K at a few hundred dollars of volume. If you process into bank accounts tied to different states, or sell into states with low thresholds, you may receive a 1099-K from a processor even on a brand that did modest volume. Do not assume a quiet brand generated no form. Confirm with every settlement entity rather than waiting to be surprised by a form your accountant never reconciled.

Corrected forms are the other thing to watch. If a processor issues a 1099-K and later finds an error, in the gross, in your taxpayer ID, in the brand attribution, they issue a corrected form. For peptide operators this happens most often around reserves and chargebacks that posted near year-end and got recategorized. Keep your own reconciliation as the source of truth so that when a corrected form arrives, you can immediately see whether it matches your books or whether the processor got it wrong. A corrected 1099-K that you cannot tie to your own records is how an operator ends up amending a return they did not need to touch.

One more peptide-specific note: a brand that was frozen mid-year still generates a 1099-K for the volume it settled before the freeze, and that form can arrive late or come from an entity you have stopped logging into. Make sure a closed account is on your settlement-entity list so its form does not slip through. If you went through a freeze this year, the freeze playbook reminds you to export full payout and transaction history while you still can, which is exactly the data you need to reconcile that final form.

Build the records the IRS and your next acquirer both want

Good 1099-K reconciliation produces a byproduct that helps you elsewhere: clean, statement-level records of volume, refunds, chargebacks, fees, and reserves per brand. That is the exact documentation a peptide-friendly acquirer asks for during underwriting when you apply or migrate. Keep it organized year-round and you serve both masters with one effort.

For an operator who has been frozen, this matters double. The next acquirer wants to see clean books and a clear story on prior processing. A reconciled 1099-K trail across your brands is part of that story.

What to do before tax season closes

• List every settlement entity that processed your peptide volume this year, including closed ones.
• Confirm you have or will receive a 1099-K from each, and match each to a brand.
• Run the gross-to-net bridge per form: minus refunds, chargebacks, fees, and held reserve, plus released reserve.
• Track reserve holds and releases by date so timing mismatches do not distort income.
• Hand your accountant the reconciliation, not just the raw forms.

None of this is tax advice, and your CPA should own the filing. What we can do is make the payments side legible. If you are tired of reconciling four 1099-K forms across four MIDs every spring, a parent account collapses that to one. Talk to an underwriter about whether your brand count and volume justify the move. Twelve questions, no hard pull, an honest answer.